omeprazole sulfone has been researched along with omeprazole in 46 studies
| Studies (omeprazole sulfone) | Trials (omeprazole sulfone) | Recent Studies (post-2010) (omeprazole sulfone) | Studies (omeprazole) | Trials (omeprazole) | Recent Studies (post-2010) (omeprazole) |
|---|---|---|---|---|---|
| 50 | 12 | 17 | 9,085 | 2,737 | 1,487 |
| Protein | Taxonomy | omeprazole sulfone (IC50) | omeprazole (IC50) |
|---|---|---|---|
| Mcl-1 | Homo sapiens (human) | 3.1448 | |
| cGMP-specific 3',5'-cyclic phosphodiesterase | Homo sapiens (human) | 0.28 | |
| Potassium-transporting ATPase alpha chain 1 | Homo sapiens (human) | 1.45 | |
| Cytochrome P450 2C19 | Homo sapiens (human) | 2.315 | |
| Potassium-transporting ATPase subunit beta | Homo sapiens (human) | 1.45 | |
| WD repeat-containing protein 5 | Homo sapiens (human) | 1.7 | |
| Glutathione S-transferase omega-1 | Homo sapiens (human) | 4.6 | |
| Histone-lysine N-methyltransferase 2A | Homo sapiens (human) | 1.7 | |
| Muscarinic acetylcholine receptor | Cavia porcellus (domestic guinea pig) | 3.8 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (6.52) | 18.7374 |
| 1990's | 9 (19.57) | 18.2507 |
| 2000's | 21 (45.65) | 29.6817 |
| 2010's | 12 (26.09) | 24.3611 |
| 2020's | 1 (2.17) | 2.80 |
| Authors | Studies |
|---|---|
| Afzelius, L; Andersson, TB; Baroni, M; Cruciani, G; Karlén, A; Masimirembwa, CM; Mecucci, S; Zamora, I | 1 |
| Isoherranen, N; Lutz, JD | 1 |
| Chiba, K; Ishizaki, T; Kobayashi, K; Lee, KH; Shin, SG; Sohn, DR | 1 |
| Andersson, T; Lagerström, PO; Lundborg, P; Regårdh, CG; Skånberg, I | 1 |
| Andersson, T; Bodemar, G; Larsson, R; Naesdal, J; Regårdh, CG; Skånberg, I; Walan, A | 1 |
| Jones, DB; Mihaly, GW; Morgan, DJ; Smallwood, RA; Webster, LK | 1 |
| Louis, WJ; Mihaly, GW; Prichard, PJ; Smallwood, RA; Yeomans, ND | 1 |
| Chiba, K; Ishizaki, T; Kobayashi, K; Kuroiwa, Y; Tani, M | 1 |
| Chiba, K; Ishizaki, T; Kamataki, T; Kobayashi, K; Manabe, K; Tani, M | 1 |
| Brockmöller, J; Esdorn, F; Roots, I; Rost, KL | 1 |
| Roots, I; Rost, KL | 1 |
| Houston, JB; Zomorodi, K | 1 |
| Ashton, M; Bertilsson, L; Dinh, XH; Le, DC; Lykkesfeldt, J; Nguyen, DS; Nguyen, TN; Nguyen, VH; Svensson, US; Trinh, NH | 1 |
| Tassaneeyakul, W; Vannaprasaht, S; Yamazoe, Y | 1 |
| Farrán, R; García-Encina, G; Martínez, L; Puig, S | 1 |
| Abelö, A; Andersson, TB; Antonsson, M; Naudot, AK; Skånberg, I; Weidolf, L | 1 |
| He, N; Huang, SL; Shu, Y; Wang, LS; Wang, W; Xiao, WM; Xu, ZH; Zhou, HH | 1 |
| Jeong, JE; Park, JY; Yim, DS | 1 |
| Huang, SL; Shu, Y; Wang, LS; Wang, W; Xiao, WM; Zhou, HH | 1 |
| Chow, AH; Chow, MS; Tomlinson, B; Waye, MM; Yin, OQ | 2 |
| Bertilsson, L; Kim, PS; Lee, DH; Park, CS; Roh, HK; Sagar, M; Seensalu, R; Tybring, G | 1 |
| Ishizawa, Y; Sasaki, M; Takahata, T; Tateishi, T; Yasui-Furukori, N | 1 |
| Bravo, E; Galera, R; Martínez-Lozano, C; Pérez-Ruiz, T; Sanz, A | 1 |
| Hofmann, U; Klotz, U; Leodolter, A; Malfertheiner, P; Schaeffeler, E; Schwab, M; Treiber, G | 1 |
| Cervantes, R; González, H; Hoyo-Vadillo, C; Mata, N; Ortiz, AC; Ramírez-Mayans, J; Rincón, V; Romero, E; Sosa, C; Venturelli, CR; Zarate, F | 1 |
| Bertino, JS; Kim, MJ; Nafziger, AN; Sellers, EM; Zhang, Y | 1 |
| Böttiger, Y | 1 |
| Brown, KC; Kashuba, AD; Rezk, NL | 1 |
| Hultman, Ia; Liljeblad, M; Stenhoff, H | 1 |
| Bottoli, CB; Collins, CH; Ribani, M | 1 |
| Chen, Y; Fan, L; Hu, DL; Huang, RX; Huang, YF; Wang, D; Wang, G; Wang, LS; Zhang, W; Zhou, HH | 1 |
| Sugimoto, K; Tateishi, T; Uno, T | 1 |
| Eom, SO; Jin, SK; Kang, TS; Kim, JI; Lee, HJ; Roh, J | 1 |
| Aklillu, E; Aminy, A; Bijnsdorp, A; Diczfalusy, U; Engidawork, E; Gebeyehu, E | 1 |
| Baldwin, RM; Capparelli, EV; Ingelman-Sundberg, M; Lawson, EB; Ma, JD; Rosenborg, S; Wu, JC; Yim, DS; Yin, OQ | 1 |
| Aregbe, AO; Desta, Z; Flockhart, DA; Michaud, V; Ogburn, E; Quigg, TC; Thong, N | 1 |
| Akamine, Y; Shiohira, H; Tateishi, T; Uno, T; Yamada, S; Yasui-Furukori, N | 1 |
| Davis, C; Isoherranen, N; Lutz, JD; Sager, JE; Shirasaka, Y | 1 |
| Ahmad, L; Iqbal, Z; Nasir, F; Nazir, S; Shah, Y | 1 |
| Dorado, RM; Nevado, JJ; Peñalvo, GC; Robledo, VR | 1 |
| Barocelli, E; Bettini, R; Castrati, L; Colombo, P; Elviri, L; Flammini, L; Rossi, A | 1 |
| Ahmad, L; Ahmad, S; Iqbal, Z; Nazir, S | 1 |
| Ahmad, L; Iqbal, Z; Khan, A; Khan, I; Khan, MI; Khuda, F; Nazir, S; Shah, Y | 1 |
| Aboagye, EO; Clarke, S; Edwards, RJ; Lee, P; Liddle, C; Lozan-Kuehne, JP; Maslen, L; Ramaswami, R; Sharma, R; Trousil, S | 1 |
| Ferlini Agne, G; Franklin, S; Knych, H; Somogyi, AA; Sykes, B | 1 |
1 review(s) available for omeprazole sulfone and omeprazole
| Article | Year |
|---|---|
Comparative pharmacokinetics of Omeprazole and its metabolites in poor and extensive metabolizer Pakistani healthy volunteers and a review of different studies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Area Under Curve; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Genotype; Healthy Volunteers; Humans; Omeprazole | 2018 |
12 trial(s) available for omeprazole sulfone and omeprazole
| Article | Year |
|---|---|
Formation of omeprazole sulphone but not 5-hydroxyomeprazole is inhibited by grapefruit juice.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Beverages; Citrus; Cross-Over Studies; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Enzyme Inhibitors; Female; Humans; Male; Mixed Function Oxygenases; Omeprazole; Time Factors | 2000 |
Omeprazole as a CYP2C19 marker in Chinese subjects: assessment of its gene-dose effect and intrasubject variability.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Asian People; Cross-Over Studies; Cytochrome P-450 CYP2C19; Enzyme Inhibitors; Gene Dosage; Humans; Hydroxylation; Male; Mephenytoin; Mixed Function Oxygenases; Omeprazole; Polymerase Chain Reaction; Polymorphism, Genetic; Polymorphism, Restriction Fragment Length; Reference Values | 2004 |
Omeprazole treatment of Korean patients: effects on gastric pH and gastrin release in relation to CYP2C19 geno- and phenotypes.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Female; Gastric Acidity Determination; Gastrins; Genotype; Humans; Hydrogen-Ion Concentration; Korea; Male; Middle Aged; Mixed Function Oxygenases; Omeprazole; Phenotype; Stomach Diseases | 2004 |
Esomeprazole-induced healing of gastroesophageal reflux disease is unrelated to the genotype of CYP2C19: evidence from clinical and pharmacokinetic data.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Case-Control Studies; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Enzyme Inhibitors; Esomeprazole; Female; Gastroesophageal Reflux; Genotype; H(+)-K(+)-Exchanging ATPase; Half-Life; Humans; Male; Middle Aged; Mixed Function Oxygenases; Omeprazole; Prospective Studies; Proton Pump Inhibitors; Time Factors | 2005 |
Use of omeprazole sulfone in a single plasma sample as a probe for CYP3A4.
Topics: Adult; Aged; Aryl Hydrocarbon Hydroxylases; Carbamazepine; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Activators; Enzyme Inhibitors; Female; Humans; Ketoconazole; Male; Middle Aged; Mixed Function Oxygenases; Omeprazole; Pharmacogenetics | 2006 |
Herbal medicine yin zhi huang induces CYP3A4-mediated sulfoxidation and CYP2C19-dependent hydroxylation of omeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Area Under Curve; Artemisia; Aryl Hydrocarbon Hydroxylases; Cross-Over Studies; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Drug Combinations; Drugs, Chinese Herbal; Genotype; Herb-Drug Interactions; Humans; Hydroxylation; Male; Omeprazole; Plants, Medicinal; Safrole | 2007 |
CYP2C19 haplotypes in Koreans as a marker of enzyme activity evaluated with omeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Alleles; Anti-Ulcer Agents; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Asian People; Cytochrome P-450 CYP2C19; Female; Half-Life; Haplotypes; Humans; Korea; Male; Omeprazole; Polymorphism, Single Nucleotide; Young Adult | 2009 |
Omeprazole limited sampling strategies to predict area under the concentration-time curve ratios: implications for cytochrome P450 2C19 and 3A phenotyping.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Anti-Ulcer Agents; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Asian People; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Female; Genotype; Humans; Male; Models, Biological; Omeprazole; Phenotype; White People; Young Adult | 2012 |
Induction of CYP2C19 and CYP3A activity following repeated administration of efavirenz in healthy volunteers.
Topics: Adult; Alkynes; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Drug Interactions; Enzyme Induction; Enzyme Inhibitors; Female; Humans; Hydroxylation; Male; Omeprazole; Reverse Transcriptase Inhibitors | 2012 |
Pharmacokinetics of omeprazole and its metabolites in three phases of menstrual cycle.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Area Under Curve; Biotransformation; Chromatography, High Pressure Liquid; Chromatography, Reverse-Phase; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Female; Follicular Phase; Healthy Volunteers; Humans; Luteal Phase; Menstrual Cycle; Menstruation; Metabolic Clearance Rate; Omeprazole; Proton Pump Inhibitors; Spectrophotometry, Ultraviolet | 2015 |
Variation in pharmacokinetics of omeprazole and its metabolites by gender and CYP2C19 genotype in Pakistani male and female subjects.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Area Under Curve; Biotransformation; Cytochrome P-450 CYP2C19; Female; Heterozygote; Homozygote; Humans; Hydroxylation; Linear Models; Male; Metabolic Clearance Rate; Models, Biological; Omeprazole; Pakistan; Pharmacogenetics; Phenotype; Proton Pump Inhibitors; Sex Factors; Young Adult | 2016 |
Altered cytochrome 2E1 and 3A P450-dependent drug metabolism in advanced ovarian cancer correlates to tumour-associated inflammation.
Topics: Adult; Aged; Aged, 80 and over; C-Reactive Protein; Caffeine; Chlorzoxazone; Cytochrome P-450 Enzyme System; Cytokines; Dextromethorphan; Female; Humans; Inflammation; Middle Aged; Omeprazole; Ovarian Neoplasms | 2019 |
33 other study(ies) available for omeprazole sulfone and omeprazole
| Article | Year |
|---|---|
Conformer- and alignment-independent model for predicting structurally diverse competitive CYP2C9 inhibitors.
Topics: Amino Acids; Aryl Hydrocarbon Hydroxylases; Binding Sites; Cytochrome P-450 CYP2C9; Enzyme Inhibitors; Models, Molecular; Molecular Conformation; Molecular Structure; Quantitative Structure-Activity Relationship | 2004 |
Prediction of relative in vivo metabolite exposure from in vitro data using two model drugs: dextromethorphan and omeprazole.
Topics: Dextromethorphan; Humans; Microsomes, Liver; Omeprazole; Predictive Value of Tests | 2012 |
Disposition kinetics and metabolism of omeprazole in extensive and poor metabolizers of S-mephenytoin 4'-hydroxylation recruited from an Oriental population.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Humans; Hydroxylation; Korea; Male; Mephenytoin; Omeprazole | 1992 |
The pharmacokinetics of omeprazole in humans--a study of single intravenous and oral doses.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Biological Availability; Biotransformation; Feces; Half-Life; Humans; Injections, Intravenous; Male; Omeprazole | 1990 |
Pharmacokinetics of [14C]omeprazole in patients with impaired renal function.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Benzimidazoles; Blood Proteins; Female; Humans; Kidney Failure, Chronic; Kinetics; Male; Mathematics; Middle Aged; Omeprazole | 1986 |
Effect of hypoxia on oxidative and reductive pathways of omeprazole metabolism by the isolated perfused rat liver.
Topics: Animals; Benzimidazoles; Hypoxia; Lactates; Lactic Acid; Liver; Male; Omeprazole; Oxidation-Reduction; Oxygen; Perfusion; Pyruvates; Pyruvic Acid; Rats; Rats, Inbred Strains | 1985 |
Simultaneous high-performance liquid chromatographic analysis of omeprazole and its sulphone and sulphide metabolites in human plasma and urine.
Topics: Adult; Benzimidazoles; Chromatography, High Pressure Liquid; Humans; Kinetics; Male; Omeprazole; Tablets, Enteric-Coated | 1983 |
Development and preliminary application of a high-performance liquid chromatographic assay for omeprazole metabolism in human liver microsomes.
Topics: Chromatography, High Pressure Liquid; Humans; Microsomes, Liver; Omeprazole; Proton Pumps; Reproducibility of Results | 1994 |
Oxidative metabolism of omeprazole in human liver microsomes: cosegregation with S-mephenytoin 4'-hydroxylation.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; Humans; Hydroxylation; In Vitro Techniques; Kinetics; Microsomes, Liver; Mixed Function Oxygenases; Omeprazole; Oxidation-Reduction; Sulfur | 1993 |
Phenocopies of poor metabolizers of omeprazole caused by liver disease and drug treatment.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Anti-Ulcer Agents; Anticonvulsants; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; Female; Genotype; Humans; Liver Diseases; Male; Mephenytoin; Middle Aged; Mixed Function Oxygenases; Omeprazole; Peptic Ulcer; Phenotype; Polymorphism, Genetic | 1995 |
Nonlinear kinetics after high-dose omeprazole caused by saturation of genetically variable CYP2C19.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; Enzyme Inhibitors; Female; Genetic Variation; Humans; Male; Middle Aged; Mixed Function Oxygenases; Omeprazole; Phenotype; Proton Pump Inhibitors | 1996 |
Selectivity of omeprazole inhibition towards rat liver cytochromes P450.
Topics: 7-Alkoxycoumarin O-Dealkylase; Animals; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Diazepam; Ethylmorphine-N-Demethylase; Ketoconazole; Male; Microsomes, Liver; Omeprazole; Rats; Rats, Sprague-Dawley; Substrate Specificity | 1997 |
Artemisinin induces omeprazole metabolism in human beings.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Antimalarials; Area Under Curve; Artemisinins; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Enzyme Inhibitors; Humans; Male; Middle Aged; Mixed Function Oxygenases; Omeprazole; Reference Values; Sesquiterpenes; Time Factors | 1998 |
Validation of an automated liquid chromatographic method for omeprazole in human plasma using on-line solid-phase extraction.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Automation; Chromatography, High Pressure Liquid; Drug Stability; Flow Injection Analysis; Humans; Omeprazole; Quality Control; Reproducibility of Results | 1999 |
Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; Humans; In Vitro Techniques; Isoenzymes; Kinetics; Microsomes, Liver; Mixed Function Oxygenases; Omeprazole; Stereoisomerism | 2000 |
5-hydroxylation of omeprazole by human liver microsomal fractions from Chinese populations related to CYP2C19 gene dose and individual ethnicity.
Topics: Adult; Antibodies, Monoclonal; Aryl Hydrocarbon Hydroxylases; China; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Ethnicity; Gene Dosage; Genotype; Humans; Hydroxylation; Mephenytoin; Microsomes, Liver; Mixed Function Oxygenases; Omeprazole; Substrate Specificity; Troleandomycin | 2000 |
Assay of omeprazole and omeprazole sulfone by semi-microcolumn liquid chromatography with mixed-function precolumn.
Topics: Anti-Ulcer Agents; Calibration; Chromatography, Liquid; Humans; Omeprazole; Quality Control; Reproducibility of Results | 2001 |
Probing CYP2C19 and CYP3A4 activities in Chinese liver microsomes by quantification of 5-hydroxyomeprazole and omeprazole sulphone.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antibodies, Monoclonal; Aryl Hydrocarbon Hydroxylases; Asian People; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Microsomes, Liver; Mixed Function Oxygenases; Omeprazole | 2000 |
Pharmacogenetics and herb-drug interactions: experience with Ginkgo biloba and omeprazole.
Topics: Adult; Aryl Hydrocarbon Hydroxylases; Asian People; Cytochrome P-450 CYP2C19; Enzyme Inhibitors; Ginkgo biloba; Herb-Drug Interactions; Humans; Male; Mixed Function Oxygenases; Omeprazole; Pharmacogenetics; Plant Extracts; Time Factors | 2004 |
The effect of aging on the relationship between the cytochrome P450 2C19 genotype and omeprazole pharmacokinetics.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Aging; Alleles; Analysis of Variance; Anti-Ulcer Agents; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Genotype; Heterozygote; Homozygote; Humans; Linear Models; Mixed Function Oxygenases; Mutation; Omeprazole | 2005 |
Determination of omeprazole, hydroxyomeprazole and omeprazole sulfone using automated solid phase extraction and micellar electrokinetic capillary chromatography.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Electrophoresis, Capillary; Micelles; Omeprazole; Pharmaceutical Preparations | 2006 |
Metabolism of omeprazole after two oral doses in children 1 to 9 months old.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Female; Gene Frequency; Humans; Infant; Infant, Newborn; Male; Mexico; Mixed Function Oxygenases; Omeprazole; Phenotype | 2005 |
Use of omeprazole as a CYP3A probe drug: effect of sex and menstrual cycle phase on CYP3A activity in healthy Caucasian adults.
Topics: Adult; Biomarkers; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Enzyme Inhibitors; Female; Humans; Male; Menstrual Cycle; Middle Aged; Omeprazole; Progesterone; Sex Factors; White People | 2006 |
A simple and sensitive bioanalytical assay for simultaneous determination of omeprazole and its three major metabolites in human blood plasma using RP-HPLC after a simple liquid-liquid extraction procedure.
Topics: Chromatography, High Pressure Liquid; Drug Stability; Humans; Molecular Structure; Omeprazole; Reproducibility of Results | 2006 |
Determination of esomeprazole and its two main metabolites in human, rat and dog plasma by liquid chromatography with tandem mass spectrometry.
Topics: Animals; Calibration; Chromatography, Liquid; Dogs; Esomeprazole; Humans; Molecular Structure; Omeprazole; Rats; Reproducibility of Results; Tandem Mass Spectrometry | 2007 |
Validation of chromatographic methods: evaluation of detection and quantification limits in the determination of impurities in omeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Chromatography, High Pressure Liquid; Drug Contamination; Omeprazole; Uncertainty | 2007 |
Effects of the CYP3A5 genotype on omeprazole sulfoxidation in CYP2C19 PMs.
Topics: Adult; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Female; Genotype; Humans; Male; Omeprazole | 2008 |
Sex and CYP3A5 genotype influence total CYP3A activity: high CYP3A activity and a unique distribution of CYP3A5 variant alleles in Ethiopians.
Topics: Adult; Alleles; Black People; Cholesterol; Cytochrome P-450 CYP3A; Ethiopia; Female; Genetic Variation; Genotype; Humans; Hydroxycholesterols; Male; Omeprazole; Sex Factors; Young Adult | 2011 |
The (R)-omeprazole hydroxylation index reflects CYP2C19 activity in healthy Japanese volunteers.
Topics: Alleles; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2C19; Drug Monitoring; Exons; Genetic Association Studies; Humans; Hydroxylation; Japan; Metabolic Detoxication, Phase I; Omeprazole; Pilot Projects; Polymorphism, Genetic; Proton Pump Inhibitors; Stereoisomerism | 2013 |
Inhibition of CYP2C19 and CYP3A4 by omeprazole metabolites and their contribution to drug-drug interactions.
Topics: Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Enzyme Inhibitors; Humans; Omeprazole | 2013 |
Simultaneous determination of omeprazole and their main metabolites in human urine samples by capillary electrophoresis using electrospray ionization-mass spectrometry detection.
Topics: Chromatography, High Pressure Liquid; Electrophoresis, Capillary; Humans; Omeprazole; Spectrometry, Mass, Electrospray Ionization | 2014 |
Development and validation of a DESI-HRMS/MS method for the fast profiling of esomeprazole and its metabolites in rat plasma: a pharmacokinetic study.
Topics: Animals; Area Under Curve; Biotransformation; Chromatography, High Pressure Liquid; Esomeprazole; Limit of Detection; Liquid-Liquid Extraction; Male; Omeprazole; Proton Pump Inhibitors; Rats; Rats, Wistar; Reference Standards; Reproducibility of Results; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry | 2016 |
Identification and kinetics of microsomal and recombinant equine liver cytochrome P450 enzymes responsible for in vitro metabolism of omeprazole.
Topics: Animals; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Horses; Humans; Kinetics; Liver; Microsomes, Liver; Omeprazole; Sulfones | 2023 |